SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GenVec - GNVC
GNVC 7.1930.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: caly who wrote (12)4/2/2010 12:18:39 AM
From: mlkr  Read Replies (1) of 106
 
1. GenVec shares implode on pancreatic cancer trial failure
By Maureen Martino Comment | Forward | Tweet thisShare on FacebookShare on LinkedIn

GenVec is reeling after its lead therapy TNFerade flunked a Phase III trial for pancreatic cancer. An interim analysis found that the gene therapy was unlikely to prove effective, causing the developer to discontinue the trial and cancel the TNFerade program. "We are disappointed that the PACT trial did not provide sufficient evidence of the clinical effectiveness of TNFerade to warrant completion of the trial," says Mark Thornton, SVP of product development at GenVec. The news caused GenVec's stock to plunge from almost $3 a share at yesterday's closing to under $1 a share this morning.

The loss of its lead program leaves GenVec with several other earlier-stage programs. Last month, the company inked a $213 million pact with Novartis for its preclinical program for hearing loss and balance disorders. And GenVec landed $22 million development deal with Science Applications International last November to develop new HIV and flu vaccines.

"As our shareholders know, in addition to TNFerade our research and development pipeline consists of a number of funded vaccine programs based on our industry-leading technology," Thornton says in a statement. "At this time, we will continue to focus on those programs and supporting our collaboration with Novartis to develop treatments for hearing loss," he adds.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News